Ingrid Meinl
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: January 10, 2025
Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 10, 2022
Relapse-independent multiple sclerosis progression under natalizumab.
Journal: Brain communications
Published: April 25, 2021
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 11, 2020
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 02, 2020
Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.
Journal: Journal of neuroinflammation
Published: December 19, 2019
Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 07, 2019
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 19, 2017
Features of Human CD3+CD20+ T Cells.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: January 15, 2016
PML risk stratification using anti-JCV antibody index and L-selectin.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 18, 2015
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 21, 2014
Last Updated: 09/26/2026